Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06499857 · ClinicalTrials.gov registry record · Phase 3
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation and Overweight or Obesity, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT06499857: Recruiting Phase 3 study of Atrial Fibrillation and Overweight or Obesity, sponsored by University of Chicago.
NCT06499857 is a Phase 3 study of Atrial Fibrillation and Overweight or Obesity that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 200 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06499857, a Phase 3 study of Atrial Fibrillation and Overweight or Obesity, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Primary Outcome
Defined by length of time detected by routine outpatient monitoring (Holter, mobile telemetry, or implantable loop recorder).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (2)
Arizona
- The University of Arizona College of Medicine- Phoenix - Phoenix
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
What NCT06499857 shows while recruiting
NCT06499857 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06499857 reports a single indexed study location in Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT06499857 about?
NCT06499857 is a clinical study titled "Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation". The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
What is the current status of trial NCT06499857?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-04-14. Estimated completion is 2028-06.
What conditions does trial NCT06499857 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Overweight or Obesity.
What interventions are being tested in trial NCT06499857?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06499857?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06499857 being conducted?
This trial has 2 study locations across Arizona, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06499857's enrollment target sits among peer trials
200 101st of 202 higher than 97 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI